Virtus ETF Advisers’s ESSA Pharma EPIX Stock Holding History

Virtus ETF Advisers’s Portfolio EPIX Stock Details EPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-12,885	Closed	-$80K	–	454
2022 Q1	$80K	Sell	12,885 -758	-6%	-$6.66K	0.04%	335
2021 Q4	$194K	Buy	13,643 +5,817	+74%	+$64.8K	0.07%	219
2021 Q3	$63K	Sell	7,826 -407	-5%	-$6.47K	0.03%	393
2021 Q2	$235K	Buy	+8,233	New	+$239K	0.1%	229

Other funds holding EPIX

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Virtus ETF Advisers's EPIX Position: Q2 2022 in Review

Virtus ETF Advisers sold out of ESSA Pharma (EPIX) in Q2 2022, closing a stake of 12,885 shares — an estimated $80K sold.

Virtus ETF Advisers first reported a position in EPIX in Q2 2021 and held it in 4 quarters. The position peaked at $235K in Q2 2021. 59 funds tracked by Wall St. Rank hold EPIX as of Q2 2022.

Virtus ETF Advisers reported no remaining ESSA Pharma position as of Q2 2022 after selling out during the quarter.
Virtus ETF Advisers sold 12,885 ESSA Pharma shares in Q2 2022, an estimated $80K.
Virtus ETF Advisers first reported a position in ESSA Pharma in Q2 2021 and held it in 4 quarters.
Virtus ETF Advisers's ESSA Pharma position peaked at $235K in Q2 2021.
59 funds tracked by Wall St. Rank held ESSA Pharma as of Q2 2022.

Based on Virtus ETF Advisers's 13F filing for Q2 2022, filed 12 Aug 2022.